Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01036087 · ClinicalTrials.gov registry record · Phase 2
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT01036087: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01036087 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01036087, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn how effective the combination of chemotherapy including both panitumumab, Abraxane (nab-paclitaxel), and carboplatin (PNC) and fluorouracil, epirubicin, and cyclophosphamide (FEC) used before surgery for the treatment of IBC is. The safety of PNC combination will also be studied.
Interventions
- DRUG Carboplatin
- DRUG 5-Fluorouracil
- DRUG Nab-paclitaxel
- DRUG Panitumumab
- DRUG Epirubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2010-11 |
| Est. Completion | 2022-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01036087
The ClinicalTrials.gov registry entry for NCT01036087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01036087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01036087 about?
NCT01036087 is a clinical study titled "Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer". The goal of this clinical research study is to learn how effective the combination of chemotherapy including both panitumumab, Abraxane (nab-paclitaxel), and carboplatin (PNC) and fluorouracil, epirubicin, and cyclophosphamide (FEC) used before surgery for the treatment of IBC is. The safety of PNC ...
What is the current status of trial NCT01036087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2010-11. Estimated completion is 2022-08-09.
What interventions are being tested in trial NCT01036087?
The interventions under investigation include: Carboplatin (DRUG), 5-Fluorouracil (DRUG), Nab-paclitaxel (DRUG), Panitumumab (DRUG), Epirubicin (DRUG).
Who is sponsoring clinical trial NCT01036087?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.